| Literature DB >> 29749534 |
Caroline Odewumi1, Lekan M Latinwo1, Roy Leonard Lyles2, Veera L D Badisa1, Cobb-Abdullah Ahkinyala3, Marijo Kent-First1.
Abstract
Cadmium (Cd), an economically valuable metal, is widely used in various industrial processes. Although it is of economic value, it is hazardous to human health. Cd accumulates in vital organs where it causes various diseases. Natural compounds with chelating or antioxidant properties have been tested to reduce the toxic effect of Cd. The anti‑oxidant, anti‑diabetic and hypocholesterolemic properties of fenugreek (Trigonella foenum-graecum) leaves make it a candidate for investigation as protective agent against Cd‑induced toxicity. In the present study, the protective effects of fenugreek leaf extract (FLE) on cell viability, morphology, and whole genomic transcription in cadmium chloride (CdCl2)‑treated rat liver cells were analyzed. The cells were treated with 25 µM CdCl2 alone, or co‑treated with 5 µg/ml FLE for 48 h. The co‑treated cells were pretreated with FLE for 2 or 4 h, followed by CdCl2 treatment. Genomic transcription analysis was performed in the CdCl2‑treated cells following treatment for 6 h. The CdCl2 caused a significant decrease in viability (35.8±4.1%) and morphological distortion of the cells, compared with the untreated control cells; whereas 4 h pretreatment with FLE (5 µg/ml) reversed the Cd‑induced morphology alteration and increased the cell viability to 102±3.8%. Genomic transcription analysis of the CdCl2 only‑treated cells showed 61 upregulated and 124 downregulated genes, compared with 180 upregulated and 162 downregulated genes in the FLE pretreated cells. Furthermore, 37 and 26% of the affected total genomic genes in the CdCl2 only‑treated cells were involved in binding and catalytic activities, respectively, whereas 50 and 20% of the genes in the FLE pretreated cells were involved in binding and catalytic activities, respectively. In conclusion, these results suggested that genome transcriptome modulation may be important in the protective effect of FLE against Cd‑induced toxicity in normal rat liver cells.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29749534 PMCID: PMC6034912 DOI: 10.3892/ijmm.2018.3669
Source DB: PubMed Journal: Int J Mol Med ISSN: 1107-3756 Impact factor: 4.101
Figure 1Protective effect of FLE on the viability of CdCl2-treated cells. The cells were treated with CdCl2 for 48 h with or without FLE pretreatment and viability was measured using a crystal violet assay (n=3). *P<0.05, compared with the control; #P<0.05, compared with CdCl2 alone. Statistical analysis performed using Dunnett's multiple comparison test. FLE, fenugreek leaf extract; CdCl2, cadmium chloride.
Figure 2Protective effect of FLE on the morphological changes of CdCl2-treated cells. The cells were treated (A) without CdCl2, or treated with (B) 25 µM CdCl2 for 48 h, (C) pretreated with FLE (5 µg/ml) for 4 h followed by CdCl2 for 48 h, or (D) treated with FLE (5 µg/ml) alone. Images were captured with a Kodak digital camera under the Nikon Diaphot phase contrast microscope (magnification, ×10). FLE, fenugreek leaf extract; CdCl2, cadmium chloride.
Figure 3Differentially expressed genes in different treatment groups. The cells were treated with CdCl2 alone, FLE alone, or pretreated with FLE for 4 h followed by CdCl2 for 6 h. The total RNA isolated from these treatment groups was subjected to whole genome microarray analysis using an Affymetrix RG230 PM array and the data were analyzed using Partek Express software to quantify differentially expressed genes with a fold change range of >2 and <−2, compared with the control. The total number of differentially expressed genes in each treatment group is indicated in parentheses. FLE, fenugreek leaf extract; CdCl2, cadmium chloride.
Number of differentially expressed genes in the treatment groups.
| Fold change range | CdCl2 | CdCl2 + FLE | FLE |
|---|---|---|---|
| 1-2 | 61 | 180 | 77 |
| <−15 | 1 | 1 | 0 |
| >−14-<−10 | 2 | 2 | 0 |
| >−10-<−2 | 121 | 159 | 31 |
CdCl2, cadmium chloride; FLE, fenugreek leaf extract.
Figure 4Percentages of genes for each molecular function in CdCl2 alone-treated cells. The cells were treated with CdCl2 alone for 6 h and isolated total RNA was subjected to whole genome microarray analysis using an Affymetrix RG230 PM array, with data analyzed using Partek Express software to show the percentage of genes for each molecular function. CdCl2, cadmium chloride.
Figure 5Percentage of genes for each molecular function in cells pretreated with FLE followed by treatment with CdCl2. The cells were pretreated with FLE for 4 h followed by CdCl2 for 6 h, and total RNA was isolated and subjected to whole genome microarray analysis using an Affymetrix RG230 PM array. The data were analyzed using Partek Express software to show the percentage of genes for each molecular function. FLE, fenugreek leaf extract; CdCl2, cadmium chloride.
Prominently upregulated genes in cadmium chloride-treated cells.
| Gene | Fold change | Function |
|---|---|---|
| γ-2a immunoglobulin heavy chain | 7.34 | Antigen binding |
| Similar to RIKEN cDNA 1700016G05 | 4.28 | Serine-type endopeptidase activity |
| Transmembrane protein 106B | 3.1 | Uncharacterized |
| YY1 transcription factor | 2.76 | DNA binding, metal ion binding |
| Glycosyltransferase 25 domain containing 1 | 2.53 | Transferase activity, procollagen galactosyltransferase activity |
| Prefoldin subunit 5 | 2.46 | Unfolded protein binding |
| Transcription factor activator protein-2, α | 2.37 | RNA polymerase II core promoter sequence-specific, DNA binding, chromatin binding, RNA polymerase II core promoter proximal region sequence-specific, DNA binding transcription factor activity involved in negative regulation of transcription |
| Phosphatidic acid phosphatase type 2B | 2.32 | Integrin binding, lipid phosphatase activity |
| Selenoprotein W1 | 2.28 | Antioxidant activity, selenium binding |
| Spermatogenesis associated, serine-rich 2-like | 2.27 | Uncharacterized |
Prominently upregulated genes in cells pretreated with fenugreek leaf extract followed by cadmium chloride treatment.
| Gene | Fold change | Function |
|---|---|---|
| γ-2a immunoglobulin heavy chain | 6.76 | Antigen binding |
| BMP-binding endothelial regulator | 5.01 | Inhibitor of bone morphogenetic protein function |
| Similar to RIKEN cDNA 1700016G05 | 4.41 | Serine-type endopeptidase activity |
| Periostin, osteoblast specific factor | 3.69 | Heparin binding |
| Chemokine (C-X-C motif) ligand 12 | 3.57 | Chemokine receptor binding, chemokine activity |
| Fibromodulin | 3.48 | Collagen binding |
| Activating transcription factor 5 | 3.41 | Heat shock protein binding |
| Ribosomal L24 domain containing 1 | 3.3 | Ribosome biogenesis |
| Calpastatin | 3.16 | Calcium-dependent cysteine-type endopeptidase inhibitor activity, protease binding |
| SH3 domain binding glutamic acid-rich protein like | 3.12 | Electron carrier activity, protein disulfide oxidore ductase activity |
Prominently downregulated genes in cadmium chloride-treated cells.
| Gene name | Fold change | Function |
|---|---|---|
| Aldehyde oxidase 1 | −10.48 | NAD binding, electron carrier activity, iron ion binding |
| Solute carrier family 7 (cationic amino acid transporter, y+ system), member 11 | −9.2 | Amino acid transmembrane transporter activity |
| Heme oxygenase (decycling) 1 | −6.24 | Enzyme binding, heme binding, metal ion binding, protein binding, heme oxygenase activity, oxidoreductase activity |
| ATP-binding cassette, sub-family C (CFTR/MRP), member 4 | −6.12 | ATP binding, enzyme binding, chloride channel inhibitor activity, transmembrane transporter activity |
| Solute carrier family 39 (iron-regulated transporter), member 1 | −4.7 | Iron ion transmembrane transporter activity |
| Chemokine (C-C motif) ligand 7 | −4.14 | C-C chemokine receptor activity |
| Sulfiredoxin 1 homolog ( | −4.1 | ATP binding, antioxidant activity, oxidoreductase activity, sulfiredoxin activity |
| Monoamine oxidase A | −4.07 | Flavin adenine dinucleotide binding, oxidoreductase activity, serotonin binding |
| Catalase | −3.58 | NADP binding, aminoacylase activityaminoacylase activity, antioxidant activity, heme binding, oxidoreductase activity, receptor binding |
| Adenosine monophosphate deaminase 3 | −3.46 | AMP deaminase activity, metal ion binding |
Prominently downregulated genes in cells pretreated with fenugreek leaf extract followed by cadmium chloride treatment.
| Gene | Fold change | Function |
|---|---|---|
| Metallothionein 1a | −59.21 | Cadmium ion binding, zinc ion binding |
| Metallothionein 2A | −11.63 | Cadmium ion binding, zinc ion binding |
| Aldehyde oxidase 1 | −10.03 | NAD binding, electron carrier activity, iron ion binding |
| Heme oxygenase (decycling) 1 | −9.72 | Enzyme binding, heme binding, metal ion binding, protein binding, heme oxygenase activity, oxidoreductase activity |
| Solute carrier family 7 (cationic amino acid transporter, y+ system), member 11 | −7.28 | Amino acid transmembrane transporter activity |
| Ectonucleoside triphosphate diphosphohydrolase 5 | −6.53 | Guanosine-diphosphatase activity, uridine-diphosphatase activity |
| ATP-binding cassette, sub-family C (CFTR/MRP), member 4 | −6.42 | ATP binding |
| Coenzyme Q6 homolog (yeast) | −5.05 | Flavin adenine dinucleotide binding, oxidoreductase activity, monooxygenase activity |
| Zinc finger, AN1-type domain 2A | −5 | Zinc ion binding |
| Glutamate cysteine ligase, modifier subunit | −4.97 | Glutamate-cysteine ligase activity, protein heterodimerization activity |
Percentage of altered genes in the most prominently upregulated pathways.
| Name of pathway | CdCl2 alone-treatedcells (%) | Cells pretreated with FLE followed by CdCl2 treatment (%) |
|---|---|---|
| Ribosome | 87 | 92 |
| Valine, leucine and isoleucine biosynthesis | 85 | 71 |
| DNA replication | 83 | 66 |
| Mismatch repair | 78 | – |
| Ubiquinone and other terpenoid-quinone biosynthesis | 75 | 75 |
| TCA cycle | 75 | 75 |
| Parkinson's disease | 71 | 74 |
| Sulfur metabolism | 71 | – |
| RNA transport | 70 | 64 |
| Vitamin B6 metabolism | 67 | – |
| Thiamine metabolism | – | 67 |
| Pantothenate and CoA biosynthesis | – | 65 |
| Sulfur relay system | – | 63 |
CdCl2, cadmium chloride; FLE, fenugreek leaf extract.
Percentage of altered genes in most prominently downregulated pathways.
| Name of pathway | CdCl2 alone-treated cells (%) | Cells pretreated with FLE followed by CdCl2 treatment (%) |
|---|---|---|
| D-Arginine and D-Ornithine metabolism | 100 | 100 |
| Primary bile acid biosynthesis | 89 | 89 |
| Collecting duct acid secretion | 88 | 88 |
| Amino sugars metabolism | 86 | – |
| Butirosin and neomycin biosynthesis | 86 | 86 |
| Caffeine metabolism | 80 | – |
| Amino sugars and nucleotide amino sugars and | 79 | – |
| nucleotide sugar metabolism | ||
| Pentose and glucuronate interconversions | 78 | 83 |
| Ascorbate and alderate metabolism | 65 | 75 |
| Drug metabolism | 27 | 31 |
| Metabolism of xenobiotics by cytochrome p450 | – | 84 |
| Steroid hormone biosynthesis | – | 80 |
| Retinol metabolism | – | 80 |
CdCl2, cadmium chloride; FLE, fenugreek leaf extract.